Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (21-30 of 395) with videos related to

Pageof 40
Sort By:
The Journal of Rheumatology|June 3, 2018
Excessive Pricing Causes Poor Access to BiologicsMaarten Boers
Arthritis Care & Research|February 25, 2026
Comment on article: "Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus" by Madanchi et alMaarten Boers
Annals of the Rheumatic Diseases|May 12, 2018
Designing effective graphs to get your message acrossMaarten Boers
Arthritis and Rheumatism|June 10, 2003
Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?Maarten Boers
Annals of the Rheumatic Diseases|November 7, 2020
Patient global assessment to define remission in rheumatoid arthritis:quo vadis?Maarten Boers
Arthritis and Rheumatism|June 4, 2005
Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in oppositionMaarten Boers
Arthritis Care & Research|December 19, 2022
Rheumatoid arthritis disease activity and hospitalized infection in a large US registry: comment on the article by Yun et alMaarten Boers
Arthritis and Rheumatism|May 18, 2004
Evidence for interaction between disease severity and comorbidity in rheumatoid arthritis? comment on the article by Navarro-Cano et alMaarten Boers
Arthritis and Rheumatism|October 31, 2009
The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et alMaarten Boers
Annals of Internal Medicine|November 4, 2009
Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?Maarten Boers
Pageof 40

Showing results (21-30 of 395) with videos related to

Sort By:
Pageof 40
The Journal of Rheumatology|June 3, 2018
Excessive Pricing Causes Poor Access to BiologicsMaarten Boers
Arthritis Care & Research|February 25, 2026
Comment on article: "Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus" by Madanchi et alMaarten Boers
Annals of the Rheumatic Diseases|May 12, 2018
Designing effective graphs to get your message acrossMaarten Boers
Arthritis and Rheumatism|June 10, 2003
Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?Maarten Boers
Annals of the Rheumatic Diseases|November 7, 2020
Patient global assessment to define remission in rheumatoid arthritis:quo vadis?Maarten Boers
Arthritis and Rheumatism|June 4, 2005
Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in oppositionMaarten Boers
Arthritis Care & Research|December 19, 2022
Rheumatoid arthritis disease activity and hospitalized infection in a large US registry: comment on the article by Yun et alMaarten Boers
Arthritis and Rheumatism|May 18, 2004
Evidence for interaction between disease severity and comorbidity in rheumatoid arthritis? comment on the article by Navarro-Cano et alMaarten Boers
Arthritis and Rheumatism|October 31, 2009
The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et alMaarten Boers
Annals of Internal Medicine|November 4, 2009
Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?Maarten Boers
Pageof 40